Bain Capital Life Sciences Investors, LLC Atea Pharmaceuticals, Inc. Transaction History
Bain Capital Life Sciences Investors, LLC
- $298 Million
- Q1 2025
A detailed history of Bain Capital Life Sciences Investors, LLC transactions in Atea Pharmaceuticals, Inc. stock. As of the latest transaction made, Bain Capital Life Sciences Investors, LLC holds 2,485,638 shares of AVIR stock, worth $9.3 Million. This represents 2.49% of its overall portfolio holdings.
Number of Shares
2,485,638
Previous 2,485,638
-0.0%
Holding current value
$9.3 Million
Previous $8.33 Million
10.74%
% of portfolio
2.49%
Previous 2.25%
Shares
3 transactions
Others Institutions Holding AVIR
# of Institutions
109Shares Held
48.3MCall Options Held
3.4KPut Options Held
14.5K-
Black Rock Inc. New York, NY9.12MShares$34.1 Million0.0% of portfolio
-
Bml Capital Management, LLC Zionsville, IN7.61MShares$28.5 Million18.41% of portfolio
-
Tang Capital Management LLC San Diego, CA4.8MShares$18 Million0.93% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.73MShares$17.7 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA1.98MShares$7.4 Million0.0% of portfolio
About Atea Pharmaceuticals, Inc.
- Ticker AVIR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 83,258,600
- Market Cap $311M
- Description
- Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...